

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Impact of Vaccine Prioritization Strategies on Mitigating COVID-19: An Agent-Based
Simulation Study using an Urban Region in the United States

Hanisha Tatapudi¹, Rachita Das², and Tapas K. Das¹

¹ Department of Industrial and Management System Engineering, University of South Florida, Tampa, Florida, USA.

² Miller School of Medicine, University of Miami, Miami, Florida, USA.

Corresponding author: Hanisha Tatapudi

Email: tatapudi@usf.edu

ABSTRACT

26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

Background

Approval of novel vaccines for COVID-19 had brought hope and expectations, but not without additional challenges. One central challenge was understanding how to appropriately prioritize the use of limited supply of vaccines. This study examined the efficacy of the various vaccine prioritization strategies using the vaccination campaign underway in the U.S.

Methods

The study developed a granular agent-based simulation model for mimicking community spread of COVID-19 under various social interventions including full and partial closures, isolation and quarantine, use of face mask and contact tracing, and vaccination. The model was populated with parameters of disease natural history, as well as demographic and societal data for an urban community in the U.S. with 2.8 million residents. The model tracks daily numbers of infected, hospitalized, and deaths for all census age-groups. The model was calibrated using parameters for viral transmission and level of community circulation of individuals. Published data from the Florida COVID-19 dashboard was used to validate the model. Vaccination strategies were compared using a hypothesis test for pairwise comparisons.

Results

Three prioritization strategies were examined: a minor variant of CDC's recommendation, an age-stratified strategy, and a random strategy. The impact of vaccination was also contrasted with a no vaccination scenario. The study showed that the campaign against COVID-19 in the U.S. using vaccines developed by Pfizer/BioNTech and Moderna 1) reduced the cumulative number of infections by 10% and 2) helped the pandemic to subside below a small threshold of 100 daily new reported cases sooner by approximately a month when compared to no vaccination. A comparison of the prioritization strategies showed no significant difference in their impacts on pandemic mitigation.

Conclusions

Even though vaccines for COVID-19 were developed and approved much quicker than ever before, their impact on pandemic mitigation was small as the explosive spread of the virus had already infected a significant portion of the population, thus reducing the susceptible pool. A notable observation from the study is that instead of adhering strictly to a sequential prioritizing strategy, focus should perhaps be on distributing the vaccines among all eligible

55 as quickly as possible, after providing for the most vulnerable. As much of the population worldwide is yet to be
56 vaccinated, results from this study should aid public health decision makers in effectively allocating their limited
57 vaccine supplies.

58

59 Keywords: Vaccination strategies, COVID-19, Agent-based simulation model, Vaccination policies, Vaccination
60 prioritization

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81 INTRODUCTION

82 SARS-CoV-2 and resulting COVID-19 disease has been raging world-wide since early 2020, killing over 2.0
83 million globally and nearly 450,000 in the United States by the end of January 2021 [1]. A significant winter swell
84 in cases was underway in the U.S. between November 2020 and January 2021 despite protective measures in place
85 such as face mask usage, limited contact tracing, travel restrictions, social distancing practices, and partial
86 community closures. To combat this, many promising novel vaccines were developed, of which two
87 (Pfizer/BioNTech and Moderna) were authorized for emergency use in mid-December 2020 by the U.S. Food and
88 Drug Administration (USFDA) [2]. Data from initial trials of cohorts greater than 30,000 people showed that these
89 vaccines, given in two doses, were safe and have ~95% effectiveness in preventing COVID-19 [3]. Vaccine
90 deployment in the U.S. began soon after USFDA approval.

91
92 Implementing an effective vaccination campaign was essential to dramatically reduce the infection, hospitalization,
93 and death rates, but posed many unique challenges. Vaccine prioritization and allocation strategy was at the
94 forefront of the challenges to effectively vaccinate communities. Strategy was influenced by a number of key
95 factors: 1) limited initial vaccine supply in the months following release, 2) transmission and severity of COVID-19
96 varying by segment of the population, 3) vaccine approvals only for adults, and 4) acceptability and compliance in
97 the community for two dose vaccination [4].

98
99 U.S. Centers for Disease Control (CDC) released an outline prioritizing healthcare personnel, first responders,
100 persons with high risk medical conditions for COVID-19, and older adults >65 years. These groups were given
101 priority for vaccination in phase 1, when supply was limited. In phase 2 (supply increased to begin to meet demand)
102 and phase 3 (supply was greater than demand), other population groups were vaccinated based on age and
103 availability [5]. Vaccine allocation structures with basic similarities and some key differences were used by
104 countries around the world. For example, after healthcare workers, France's vaccine allocation scheduled other
105 general workers regardless of age who they had determined to be at high risk of contracting and spreading the virus
106 due to contact with the general public. This includes retail, school, transportation, and hospitality staff [6]. Such
107 differences in vaccine prioritization strategies were untested at the time of the study and warranted modeling and
108 examination.

109

110 The goal of this paper was to investigate the impact of vaccination on the pandemic via outcome measures such as
111 numbers of infected, hospitalized, and deaths in the months following December 15, 2020 when vaccination would
112 begin in the U.S. Two specific objectives of our investigation were: 1) to assess the expected impact of the
113 vaccination program on mitigating COVID-19, and 2) to inform public health officials on the comparative benefits,
114 if any, of the different vaccine prioritization strategies. We conducted our investigation by using our agent-based
115 (AB) simulation model for COVID-19 that was presented during the early phase of the pandemic [7]. For this study,
116 we first extended calibration of our model till December 30, 2020 to ensure that our model appropriately tracked the
117 explosive increase in cases that started with the onset of winter and the year-end holiday period in 2020. We then
118 enhanced the AB simulation model by adding a framework for vaccination. This included: vaccination priorities for
119 people based on attributes including profession and age, use of two different vaccines by Pfizer/BioNTech and
120 Moderna with their contracted quantities and approximate delivery timelines, vaccine acceptance, transition period
121 between each priority group, vaccination rate, and immunity growth for vaccinated starting with the first dose.

122

123 As in [7], we implemented our calibrated AB model, augmented with vaccination, for Miami-Dade County of the
124 U.S. with 2.8 million population, which had been an epicenter of COVID-19 in the U.S. We conducted our
125 investigation by implementing a number of prioritization strategies and obtaining the corresponding numbers of total
126 infections, reported infections, hospitalizations, and deaths. The strategies implemented were 1) minor variant of the
127 CDC recommended strategy, 2) age stratified strategy, and 3) random strategy. We also implemented a no
128 vaccination case. These strategies are explained in a later section. We compared and contrasted the results to assess
129 vaccination efficacy and relative performances of the priority strategies. We made a number of key observations
130 from the results, which we believe will help public health officials around the world to choose effective vaccine
131 prioritization strategies to mitigate the negative impacts of COVID-19.

132

133 LITERATURE REVIEW

134 On a global scale, equitable and ethical distribution of vaccines for all (low, medium, and high-income) countries is
135 an important question. As the world leader in promoting global health, World Health Organization (WHO) released
136 an evidence-based framework for vaccine-specific recommendations [8]. WHO proposed vaccine prioritization for

137 three potential scenarios of transmission: community transmission, sporadic cases or cluster of cases, and no cases.
138 Each scenario has three stages and focuses on different risk groups. COVID-19 pandemic resembles “community
139 transmission.” For this, the first stage focused on healthcare workers and older adults with highest risk; second stage
140 continued the focus on older adults and people with comorbidities, sociodemographic groups, and educational staff;
141 and the third stage focused on essential workers and social/employment groups unable to physically distance
142 themselves.

143 National Academy of Sciences, Engineering, and Medicine (NAESM) developed a more comprehensive phased
144 framework for equitable allocation of COVID-19 vaccine [9]. The first phase prioritized healthcare workers and first
145 responders, people with high risk comorbidities, and older adults in crowded living conditions; second phase
146 focused on K-12 school staff and child care workers, essential workers, people with moderate risk comorbidities,
147 people living in shelters, physically and mentally disabled people and staff that provide care, employment settings
148 where social distancing was not possible, and remaining older adults; third phase prioritized young adults, children,
149 and workers; and fourth phase included everyone else. No specific studies had been presented to the literature at the
150 time of this research that had evaluated the efficacy of the proposed vaccination priorities for mitigating COVID-19.

151 A number of studies can be found in the literature on vaccination strategies for controlling outbreaks of other
152 viruses. The work presented in [10] analyzes the effect of both CDC guided targeted vaccination strategy as well as
153 a mass vaccination strategy for seasonal Influenza outbreaks in the U.S. The study found that a mass vaccination
154 policy reaped the most benefits both in terms of cost and quality-of-life years (QALYs) lost. Authors in [11] use a
155 genetic algorithm to find optimal vaccine distribution strategies that minimize illness and death for Influenza
156 pandemics with age specific attack rates similar to the 1957–1958 A(H2N2) Asian Influenza pandemic and the
157 1968–1969 A(H3N2) Hong Kong Influenza pandemic. They consider coverage percentage under varying vaccine
158 availability and developed an optimal vaccination approach that was 84% more effective than random vaccination.
159 A study reported in [12] examined vaccination to prevent interpandemic Influenza for high-risk groups and children,
160 and recommended concentrating on schoolchildren, who were most responsible for transmission, and then extended
161 to high-risk groups. A compartmental model in [13] was used to develop optimal strategies to reduce the morbidity
162 and mortality of the H1N1 pandemic. The study found that age specific vaccination schedules had the most
163 beneficial impact on mortality.

164 It can be concluded from the above review of relevant literature that there is no ‘one size fits all’ strategy for
165 vaccination to either prevent a pandemic outbreak or mitigate one. Virus epidemiology and corresponding disease
166 characteristics, as well as the efficacy and supply of the vaccine must be considered in developing an effective
167 vaccination prioritization strategy. Our paper aims to address this need by presenting a detailed AB simulation
168 modeling approach and using it to assess efficacy of vaccine prioritization strategies for COVID-19.

169

170 METHODOLOGY

171 Published COVID-19 modeling approaches were either data-driven models, as in [14]–[18], or variants of SEIR type
172 compartmental models as in [19]–[23]. Data driven models are very well suited for understanding the past
173 progression of a pandemic and also for estimating parameters characterizing virus epidemiology. However, these
174 models offer limited ability to predict the future progression of a pandemic that could be dynamically evolving with
175 regards to virus epidemiology, disease manifestations, and sociological conditions. Compartmental models, on the
176 other hand, are aggregate in nature and do not adapt well to changing dynamics of disease transmission. An AB
177 modeling approach is considered to be more suitable for a detailed accounting of individual attributes, specific
178 disease natural history, and complex social interventions [24]. Hence we adopted the AB model approach to conduct
179 our study.

180

181 The AB simulation-based methodology was particularized using data for Miami Dade County of Florida, with 2.8
182 million population, an epicenter for COVID-19 spread in the South-Eastern United States. A step by step approach
183 for building such a model for another region can be found in [7]. The methodology began by generating the
184 individual people according to the U.S. census data that gives population attributes including age (see Table A1 in
185 [7]) and occupational distribution (see Table A4 in [7]). Thereafter, it generated the households based on their
186 composition characterized by the number of adults and children (see Table A2 in [7]). The model also generated, per
187 census data, schools (see Table A3 in [7]) and the workplaces and other community locations (see Table A4 in [7]).
188 Each person was assigned a workplace and household based on the numbers, sizes, and compositions of households,
189 schools and workplaces derived from census data (see Tables A2, A3, and A4 in [7] for distribution of household,
190 schools, and workplaces, respectively). A daily (hour by hour) schedule was assigned to every individual, chosen
191 from a set of alternative schedules based on their attributes. The schedules vary between weekdays and weekends

192 and also depend on the prevailing social intervention orders (see Table A1 in Additional file 1). The methodology
193 incorporated means to implement a number of intervention orders including full and partial closures/reopening of
194 schools and workplaces [7], [25], isolation and quarantine of infected individuals and household members, use of
195 face mask, contact tracing of asymptomatic and pre-symptomatic individuals, and vaccination priorities. The
196 timeline for interventions implemented in the model are summarized in Table 1.

197

198 **Table 1:** Social intervention order timeline for Miami-Dade County

Intervention policy implemented at Miami-Dade County, Florida, U.S.	Date of implementation	Day of Simulation
<i>Stay at home policy</i>	March 17 2020	35
<i>Phase I reopening</i>	May 18 2020	97
<i>Phase II reopening</i>	June 5 2020	115
<i>Mandatory usage of face mask</i>	June 25 2020	135
<i>Contact tracing (assumed to begin)</i>	June 30 2020	140
<i>Phase III reopening</i>	September 25 2020	227
<i>School reopening</i>	September 30 2020	232
<i>Vaccination begin day</i>	December 15 2020	308

199

200 The AB model also included a number of uncertainties such as 1) time varying values of testing rates for
201 symptomatic and asymptomatic, test sensitivity, and test result reporting delay (see Table A9 in [7]), 2) self-isolation
202 compliance for symptomatic cases and quarantine compliance for susceptible household members (see Table A10 in
203 [7]), 3) time varying and age specific probabilities of ‘hospitalization among reported cases’ and ‘death among
204 hospitalized’ (see Tables A2 and A3 in Additional file 1), 4) mask usage compliance (100% compliance was
205 assumed to reduce transmission coefficient by 33% [26]), 5) contact tracing level (assumed to be at 15% based on
206 [27], [28]), 6) percentage return to school (considered to be 50% based on [29]), 7) willingness to vaccinate
207 (considered to be 60% based on survey results in [30], [31]), 8) variations in daily schedules during various phases
208 of social interventions (see Table A5 in [7]), 9) percentage of asymptomatic among infected (assumed to be 35%
209 [32]), and 10) vaccine efficacy (95% [3]).

210


211 On the first day of the simulation, the model introduced a few initial infected cases in the community and began the
212 social mixing process. Each day the model tracked the following for each person: 1) hourly movements and
213 locations based on their daily schedules that depend on age, employment status, prevailing social intervention

214 orders, and quarantine/isolation status; 2) hourly contacts with other susceptible and infected; 3) vaccination status
215 and immunity, 4) force of infection accumulation; 5) start of infection; 6) visits/consultation with a doctor (if
216 symptomatic and insured); 7) testing (if infected and visited/consulted a doctor or asymptomatic chosen for testing
217 either randomly or via contact tracing); 8) test reporting delay; 9) disease progression (if infected); 10)
218 hospitalization (if infected and acutely ill); and 11) recovery or death (if infected). The AB model reports daily and
219 cumulative values of actual infected, reported infections, hospitalized, and deaths, for each age category. A
220 schematic diagram depicting the algorithmic sequence and parameter inputs for the AB simulation model is
221 presented in Figure 1.

222

223

224



225

226


227

Figure 1: Schematic of the AB model for mimicking COVID-19 spread under social interventions and vaccination in the U.S.

228 For the susceptible, if vaccinated, since the exact immune response from vaccine was not known at the time of the
229 study, we assumed a linearly increasing partial immunity for susceptible after they received the first dose, attaining
230 full immunity after seven days after the second dose; we only considered vaccines made by Pfizer/BioNTech and
231 Moderna, for which the second dose was administered 21 and 28 days after the first dose, respectively. The model
232 updated the infection status of all individuals to account for new infections as well as disease progressions of
233 infected individuals. A pseudo-code in Figure A1 in Additional file 1 depicts the major elements and structure of the
234 AB simulation program.

235
236 For the infected, we considered the following epidemiological parameters: disease natural history with average
237 lengths of latent, incubation, symptomatic, and recovery periods; distribution of infectiousness; percent
238 asymptomatic; and fatality rate. The infected people were considered to follow a disease natural history as shown in
239 Figure 2, parameters of which can be found in Table A6 of [7]. The model assumed that the recovered cases became
240 fully immune to further COVID-19 infections. However, since this assumption was not fully supported by data at
241 the time of the study, people recovered from COVID-19 were also considered candidates for vaccination. The
242 duration and intensity of infectiousness was guided by a lognormal density function (see Figure 3). The function was
243 truncated at the average length of the infectiousness period (which was considered to be 9.5 days). Asymptomatic
244 cases were assumed to follow a similar infectiousness intensity profile but scaled by a factor α , as used in the force
245 of infection calculation (1) (see Table A4 in Additional file 1).

246




247

248

Figure 2: Disease natural history of COVID-19 [7]

249



250

251

Figure 3: Lognormal distribution function for infectiousness profile of a COVID-19 case [7]

252

253 In what follows we describe how we compute the force of infection and used in determining the probability of
 254 infection of individuals. Each susceptible was assumed to ingest viral particles from each infected they come in
 255 contact with during the day. The total amount of ingestion of viral particles for a susceptible i was measured as the
 256 force of infection (λ_i) using a modified version of the equation presented in [33]. The equation for force of infection
 257 (as presented in [33]) has three components to account for ingestions experienced from infected contacts at home,
 258 workplace/school/indoor community locations, and outdoor locations. As we had not found evidence in the literature
 259 of any significant COVID-19 transmissions at outdoor locations, we eliminated the third component and used only
 260 the first two elements of the equation as shown in (1). The first component of (1) accounts for the daily force of
 261 infection experienced by a susceptible i from those infected at home, and the second component accounts for
 262 workplace/school/indoor community locations.

263

$$264 \quad \lambda_i = \sum_{k|h_k=h_i} \frac{I_k \beta_h \kappa(t-\tau_k) \rho_k [1+C_k(\omega-1)]}{n_i^\alpha} + \sum_{j,k|l_k^j=l_i^j} \frac{I_k \beta_p^j \kappa(t-\tau_k) \rho_k [1+C_k(\omega-1)]}{m_i^j}. \quad (1)$$

265 The definitions and values of parameters of (1) can be found in Table A4 in Additional file 1. The daily force of
 266 infection was considered to accumulate. However, it was assumed that if a susceptible does not gather any additional
 267 force of infection (i.e., does not come in contact with any infected) for two consecutive days, the cumulative force of
 268 infection for the susceptible reduces to zero. At the end of each day, the cumulative value of λ_i was used to calculate
 269 the probability of infection for susceptible i as $1 - \exp^{-\lambda_i}$. This probability was used to classify a susceptible
 270 individual as infected in the simulation model.

271


272 As observed in [7], though it was implemented for a specific region, our model is quite general in its usability for
273 other urban regions with similar demography, societal characteristics, and intervention measures. In our model,
274 demographic inputs (age and household distribution, number of schools for various age groups, and number of
275 workplaces of various types and sizes) were curated from both national and local census records. Social
276 interventions vary from region to region and the related parameters can be easily updated. Similarly, the data related
277 to epidemiology of COVID-19 were unlikely to significantly vary from one region to another, though some
278 adjustments of these based on population demographics may be needed.

279

280 **Model Calibration**

281 The AB model utilized a large number of parameters, which were *demographic, epidemiological, and social*
282 *intervention parameters*. We kept almost all of the above parameters fixed at their respective chosen values and
283 calibrated the model by changing values for only a few. The calibrated parameters include the transmission
284 coefficients used in calculating force of infection at home, work, school, and community places (β_h and β_p^j) (see
285 Table A4 in Additional file 1). The choice of the values of transmission coefficients was initially guided by [34] and
286 thereafter adjusted at different points in time during the calibration period (until December 30, 2020). The only other
287 parameters that were calibrated are the number of errands in the daily schedules under various intervention
288 conditions and the percentage of workers in essential (e.g., healthcare, utility services, and grocery stores) and non-
289 essential (e.g., offices and restaurants) workplaces who physically reported to work during different intervention
290 periods (see Table A1 in Additional file 1). Calibration of the above parameters was done so that the daily
291 cumulative numbers of reported infected cases from the AB simulation model closely matched the values published
292 in the Florida COVID-19 dashboard until December 30, 2020. Figure 4 shows the cumulative values (with 95%
293 confidence intervals) as well as the daily numbers of the reported infected cases, hospitalizations, and deaths as
294 obtained from the simulation model. The dotted lines represent the actual numbers reported in the Florida COVID-
295 19 dashboard for Miami-Dade County [35], the trend of which was closely followed by the numbers obtained from
296 our AB simulation model. The actual numbers reported by the Florida COVID-19 dashboard showed large
297 variations, which was due to reporting delays.

298



299

300 **Figure 4:** Validation graphs with cumulative and daily values of infected, reported, and deaths calibrated until Dec
 301 30, 2020
 302

303 VACCINE PRIORITIZATION STRATEGIES

304 We used our AB model to examine the expected benefits of the ongoing vaccination in the U.S. using the limited
 305 supply of two types of vaccines developed by Pfizer/BioNTech and Moderna, which had the emergency approvals
 306 for distribution from the USFDA. We considered the number of vaccine doses that the two companies were
 307 contracted by the U.S. government to supply, which include the initial contracts for 100 million doses from each

308 company and the more recent contract for an additional 100 million doses from Pfizer/BioNTech. This amounted to
 309 a total of 300 million doses, which could inoculate 150 million people with two required doses. To our knowledge,
 310 the total supply was being apportioned among the states and the counties depending on the population. Florida had
 311 approximately 6.5% of the U.S. population and the Miami Dade County had 13% of Florida’s population. Hence,
 312 we assumed that Miami Dade County would receive approximately 2.54 million doses and would be able to
 313 vaccinate 1.27 million people out of the total 2.8 million population. We also assumed that the vaccine deliveries
 314 will occur in batches starting in late December 2020 till late June 2021. Our study goal was to first determine the
 315 extent of reduction in the number of infections, hospitalizations, and deaths that we can expect to realize from the
 316 vaccination process in comparison with if no vaccines were available. Thereafter, we conducted a comparative study
 317 between three different vaccination priority schemes to determine if the outcomes (number of reported cases,
 318 hospitalized, and deaths) from those were statistically significant.

	Priority 1	Priority 2	Priority 3	Priority 4	Priority 5
Age stratified strategy	<ul style="list-style-type: none"> Healthcare providers Nursing home residents Dec 15, 2020 – Jan 13, 2021 	<ul style="list-style-type: none"> People of ages 65 and over Jan 14 – Feb 12 2021 	<ul style="list-style-type: none"> People of ages 55 to 64 Feb 13 – Mar 14 2021 	<ul style="list-style-type: none"> People of ages 45 to 54 Mar 15 – Apr 13, 2021 	<ul style="list-style-type: none"> People of ages 16 to 44 Apr 14 – Jul 15, 2021
Minor CDC variant strategy	<ul style="list-style-type: none"> Healthcare providers Nursing home residents Dec 15, 2020 – Jan 13, 2021 	<ul style="list-style-type: none"> First responders Educators People of ages 75 and over Jan 14 – Feb 12, 2021 	<ul style="list-style-type: none"> People of ages 65 to 74 Feb 13 – Mar 30, 2021 	<ul style="list-style-type: none"> People of ages 16 to 64 Apr 1 – Jul 15, 2021 	<ul style="list-style-type: none"> NA
Random strategy	<ul style="list-style-type: none"> Healthcare providers and nursing home residents Dec 15 2020 – Jan 13, 2020 	<ul style="list-style-type: none"> All people of ages 16 and over Jan 14 – Jul 15, 2021 	<ul style="list-style-type: none"> NA 	<ul style="list-style-type: none"> NA 	<ul style="list-style-type: none"> NA

319
 320 **Figure 5:** Vaccine prioritization strategies examined using AB simulation model for COVID-19 in the U.S.
 321


322 The priority strategies that were examined are broadly described here; a more complete description is presented in
 323 Figure 5. In the absence of a declared timeline for transition of eligibility from one priority group to the next, we
 324 assumed 30 days between transition. This period was extended to allow all eligible and willing to be vaccinated
 325 when the phased vaccine supply fell short of the number of people in the eligible priority group. The first strategy
 326 that we implemented was a minor *variant of the CDC recommended strategy*: Priority 1: healthcare providers and

327 nursing home residents; Priority 2: first responders, educators, and people of ages 75 and over; Priority 3: people of
328 ages 65 to 74; Priority 4: people of ages 16 to 64. The CDC recommended strategy also included in priority 3 people
329 of ages 16 to 64 with specific health conditions. Since we did not track health conditions in our AB model, we
330 limited our priority 3 to people of ages 65 and above only. The second strategy that we implemented was an *age-*
331 *stratified strategy*: Priority 1: healthcare providers and nursing home residents; Priority 2: people of ages 65 and
332 over; Priority 3: people of ages 55 to 64; Priority 4: people of ages 45 to 54; Priority 5: people of ages 16 to 44. The
333 third strategy that we implemented was a *random strategy*: Priority 1: healthcare providers and nursing home
334 residents; Priority 2: all people of ages 16 and over. People with prior COVID-19 history were not excluded and
335 60% of the people were considered willing to vaccinate [30], [31].

336

337 RESULTS

338 Figure 6 shows the plots indicating the growth over time in the number of actual reported vaccinations together with
339 those from the three vaccination prioritization strategies that we had implemented. The vaccination began on
340 December 15, 2020. As evident from the figure, the vaccination growth of the CDC variant strategy aligned closely
341 with the actual reported numbers. In the random strategy, the growth in vaccination occurred faster as this strategy
342 opened eligibility to all ages 16 and above sooner than other strategies. The age dependent strategy further staggers
343 the eligibility and hence the vaccination grew slower than the CDC variant strategy. The flattening of the
344 vaccination growth curves was representative of the limited vaccine supply that was considered in our simulation.
345 The continued growth of the actual reported vaccinations (red dotted line) was indicative of the increase in vaccine
346 supplies since the time of our model implementation in December 2020.




347

348 **Figure 6:** Cumulative values of actual reported and simulated vaccinations until July 31, 2021

349

350 Figure 7 shows the trends of the cumulative numbers of infected cases, reported cases, hospitalized, and deaths from
351 the three vaccine prioritization strategies together with the no vaccination scenario until July 31, 2021 (last day of
352 simulation). Since the confidence intervals for the cumulative values of the strategies overlap significantly, for the
353 purpose of comparison, we chose to focus on the cumulative values on the last day of simulation. These are
354 presented in Table 2, which summarizes the values and their 95% confidence intervals. The table also provides the
355 time frame when the pandemic, according to the model, subsides with the new reported cases falling below the
356 threshold of 100. We note that, the reported cases presented in Figure 7 and Table 2 were obtained directly from the
357 simulation model. However, the hospitalization and death numbers were calculated by applying the time-varying
358 and age-specific probabilities (as presented in Tables A2 and A3 in Additional file 1) on the reported cases.

359



360

361 **Figure 7:** Impact of vaccination strategies on cumulative numbers of infected, reported, hospitalized, and
 362 deaths from COVID-19 until July 31, 2021

363

364 **Table 2:** Summary of expected cumulative values (with 95% confidence intervals) on July 31, 2021 obtained by the
 365 AB model for the vaccine prioritization strategies

366


Outcome \ Prioritization Strategy	Infected Cases	Reported Cases	Hospitalized	Deaths	Date when new reported cases fell below 100
No vaccination	1.71M (1.66M – 1.76M)	732K (695K – 770K)	18.7K (18.3K – 19.1K)	9K (8.8K – 9.3K)	June 12, 2021
Minor variant of CDC	1.55M (1.38M – 1.73M)	659K (567K – 752K)	17K (15.7k – 18.3k)	8K (7.2K – 8.8K)	May 17, 2021

Age stratified	1.58M (1.43M – 1.73M)	672K (589K – 754K)	17.6K (16.6k – 18.5k)	8.5K (7.9k – 8.9k)	May 22, 2021
Random	1.54M (1.32M – 1.75M)	649K (538K – 761K)	17.3K (15.9K – 18.7K)	8.4K (7.6K – 9.1K)	May 7, 2021

367
368
369 Since the performance of the three vaccine prioritization strategies, as shown in Figure 7, appeared to be similar, we
370 conducted simple pairwise statistical comparisons of the numbers of reported cases (from column 3 of Table 2)
371 using a test of hypothesis. According to the test results, the variant of the CDC strategy produced a statistically
372 significantly lower number of reported cases than no vaccination (p-value 0.0204). Similar results were found for
373 age-stratified and random strategies when compared to no vaccination. However, a comparison of the reported cases
374 among the three vaccine prioritization strategies showed no significant statistical difference (p-values near 0.4).
375 Pairwise comparison of the hospitalized and deaths (in columns 4 and 5 of Table 2) showed that the CDC variant
376 strategy produced statistically significantly lower numbers compared to no vaccination (p-values 0.0014 and 0.0015,
377 respectively). However, similar to the reported cases, the three vaccination strategies did not statistically differ
378 among themselves in terms of hospitalizations and deaths.

379
380 The numbers from Table 2 also indicate that the CDC variant strategy achieved a reduction of 9%, 10%, 9%, and
381 11% for total infected, reported cases, hospitalized, and deaths, respectively, compared to the outcomes with no
382 vaccination. Moreover, the CDC variant resulted in the pandemic subsiding below a small threshold of 100 new
383 reported cases about a month sooner when compared with no vaccination. The CDC variant strategy also spared
384 5.6% of the population from being infected. The above seemingly low impact of vaccination may be attributed to the
385 explosive growth of new reported cases that occurred in the winter months (Nov. 2020-Mar. 2021), which likely had
386 significantly reduced the pool of susceptible people.

387
388
389



390

391 **Figure 8:** Visualization of the impacts of vaccination strategies on the percentage of total population infected and
392 the total numbers of deaths on July 31, 2021

393

394

395 Figure 8 offers a further visual comparison of the impact of vaccination strategies on the percentage of population

396 infected and the total number of deaths. A few interesting observations can be made from the figure as follows. The

397 random strategy yielded the lowest percentage of population infected (even lower than CDC variant) as it made the

398 age groups most active in social mixing eligible for vaccination sooner than all other strategies. For the same reason

399 however, the random strategy yielded more deaths than CDC variant as it caused a delay in vaccination of the most

400 vulnerable elderly population who were not exclusively prioritized. Interestingly, the random strategy also performed

401 better than the age stratified strategy in both measures of infected and deaths.

402

403 CONCLUDING REMARKS

404 We have developed a detailed agent-based simulation model for mimicking the spread of COVID-19 in an urban

405 region (Miami-Dade County, Florida) of the U.S. The model was calibrated using transmission coefficients and

406 parameters guiding the daily schedules of people, and was validated using the actual reported cases from the Florida

407 COVID-19 dashboard till December 30, 2020 (see Figure 4). On this validated model, we incorporated the

408 vaccination process that started in the U.S. on December 15, 2020 using two different vaccines developed by

409 Pfizer/BioNTech and Moderna. Based on the government contracts at the time of our study, we assumed availability

410 of an estimated 2.54 million doses for Miami-Dade County to inoculate 1.27 million people (among the total

411 population of 2.8 million) on a 2 dose regimen.

412

413 Model results indicated that the use of the available vaccines reduced the spread of the virus and helped the
414 pandemic to subside below a small threshold of 100 daily new cases by mid-May 2021, approximately a month
415 sooner than if no vaccines were available. Also, the vaccination was shown to reduce the number of infections by
416 approximately 10% compared to no vaccination, which translates to sparing 5.6% of the total population from being
417 infected. We note that, even though the vaccines were developed and approved for human use at a much faster rate
418 than ever accomplished before, the accelerated growth of the infections, especially with the onset of the winter in the
419 northern hemisphere, reduced the expected benefits of vaccination.

420

421 Another noteworthy finding of this study was that there were no statistical differences between the numbers of
422 reported cases resulting from different vaccination prioritization strategies that were tested. This information should
423 give more latitude to decision makers in urban regions across the world for distribution of the limited supply of
424 COVID-19 vaccine. Our results suggested that instead of adhering strictly to a sequential prioritizing strategy, focus
425 should be on distributing the vaccines among all eligible as quickly as possible.

426

427 Though our AB model is well suited to study future progression of COVID-19 and other similar respiratory type
428 viruses, it has some limitations. The simulation model is highly granular, which while being a strength presents a
429 challenge of appropriately estimating the wide array of its input parameters. Though we have attempted to address
430 this challenge by conducting a sensitivity analysis on some of the critical parameters, such as levels of face mask
431 usage, contact tracing, societal closure, and school reopening, this analysis could be extended to many other
432 parameters. As mentioned under vaccination strategies, our model did not include health conditions that were
433 relevant to COVID-19 (like pulmonary disease, obesity, heart problems) as attributes for people. Hence, we were
434 not able to implement one element of the CDC recommended prioritization strategy that recommends people aged
435 16-64 years with underlying medical conditions to be considered in priority 3 (see Figure 5). Also, we did not
436 consider any vaccine wastage due to complexities associated with refrigeration, distribution, and human error. We
437 also assumed that vaccination of all priority groups occurred uniformly over the eligibility periods considered, which
438 may not reflect the reality. Also, at the time of the study, there was little available literature on the rate of immunity
439 growth each day from the two dose vaccines, therefore, we assumed a linear growth starting with the first dose and

440 culminating (full immunity) seven days after the second dose. Moreover, the model did not consider, the emergence
441 of new strains of virus as the pandemic progresses, and the lower level of immunity offered by the vaccine for
442 breakthrough infection. Finally, changes in the virus behavior might impact the comparative outcomes of different
443 vaccine prioritization strategies, as presented in this paper.

444

445 At the time of the publication of our study, vaccine availability is still limited in many parts of the world. Our results
446 will provide useful information for healthcare policy makers in judiciously allocating their COVID-19 vaccine
447 supply among their population. We also believe that our findings on vaccine prioritization strategies will serve as a
448 resource for the decision makers for future outbreaks of similar respiratory viruses. Finally, as only a limited number
449 of studies examining vaccine prioritization strategies have been presented to the open literature, our research makes
450 a significant addition.

451

452
453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

LIST OF ABBREVIATIONS

- AB – Agent-based
- SEIR – Susceptible – exposed – infected – recovered/removed
- SARS-CoV-2 – Severe acute respiratory syndrome coronavirus 2
- COVID-19 – Coronavirus Disease 2019
- USFDA – United States Food and Drug Administration
- CDC – Centers for Disease Control
- NAESM – National Academy of Sciences, Engineering, and Medicine
- QALY – Quality of Life Years
- WHO – World Health Organization

476

DECLARATIONS

477 **Ethics approval and consent to participate:** Individual human data was not used in our study. Only aggregate data
478 made available in Florida COVID-19 Dashboard was used.

479 **Consent for publication:** Not applicable

480 **Availability of data and materials:** The datasets used and/or analysed during the current study are available from
481 the corresponding author on reasonable request.

482 **Competing interests:** The authors declare that they have no competing interests

483 **Funding:** Not applicable

484 **Authors' contributions:**

485 Hanisha Tatapudi: Conceived and designed the model, Selection of model input parameters and data gathering,
486 Coding and testing of the model, Design and perform the experiments, Output analysis and review, Manuscript
487 preparation and review

488
489 Rachita Das: Selection of model input parameters and data gathering, Output analysis and review, Manuscript
490 preparation and review

491
492 Tapas K Das: Conceived and designed the model, Selection of model input parameters and data gathering, Coding
493 and testing of the model, Design and perform the experiments, Output analysis and review, Manuscript preparation
494 and review

495 **Acknowledgements:** Not applicable

496 **Authors' information:**

497 Corresponding author:

498 Hanisha Tatapudi – corresponding author

499 e-mail: tatapudi@usf.edu.
500 Telephone: +1 (813) 453-3577
501
502 Rachita Das
503 e-mail: rachi95@gmail.com
504 Telephone: +1 (813) 527-1133
505
506 Tapas K. Das
507 e-mail: das@usf.edu
508 Telephone: +1 (813) 843-0285
509
510

511 REFERENCES

- 512 [1] A. Jordan *et al.*, “Coronavirus in the U.S.: Latest Map and Case Count,” *NYtimes.com*, Jan. 25, 2021.
513 Accessed: Jan. 25, 2021. [Online]. Available: [https://www.nytimes.com/interactive/2020/us/coronavirus-us-](https://www.nytimes.com/interactive/2020/us/coronavirus-us-cases.html)
514 [cases.html](https://www.nytimes.com/interactive/2020/us/coronavirus-us-cases.html)
- 515 [2] “COVID-19 Vaccines,” *U.S. Food & Drug Administration*, Jan. 12, 2021. Accessed: Jan. 25, 2021. [Online].
516 Available: [https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine)
517 [19/pfizer-biontech-covid-19-vaccine](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine)
- 518 [3] “Pfizer and BioNtech conclude Phase 3 study of COVID-19 vaccine candidate, meeting all primary efficacy
519 endpoints,” *Pfizer*, Nov. 18, 2020. Accessed: Jan. 25, 2021. [Online]. Available:
520 [https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine)
521 [covid-19-vaccine](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine)
- 522 [4] J. Buckner, G. Chowell, and M. Springborn, “Optimal Dynamic Prioritization of Scarce COVID-19
523 Vaccines,” *Medrxiv*, Sep. 2020, doi: 10.1101/2020.09.22.20199174.
- 524 [5] “How CDC Is Making COVID-19 Vaccine Recommendations,” *CDC*, Dec. 30, 2020. Accessed: Jan. 25,
525 2021. [Online]. Available: [https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations-](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations-process.html)
526 [process.html](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations-process.html)
- 527 [6] L. Roope, P. Clarke, and R. Duch, “Who should get the coronavirus vaccine first? France and the UK have
528 different answers,” *The Conversation*, Nov. 16, 2020. Accessed: Jan. 25, 2021. [Online]. Available:
529 [https://theconversation.com/who-should-get-the-coronavirus-vaccine-first-france-and-the-uk-have-different-](https://theconversation.com/who-should-get-the-coronavirus-vaccine-first-france-and-the-uk-have-different-answers-149875)
530 [answers-149875](https://theconversation.com/who-should-get-the-coronavirus-vaccine-first-france-and-the-uk-have-different-answers-149875)
- 531 [7] H. Tatapudi, R. Das, and T. Das, “Impact assessment of full and partial stay-at-home orders, face mask usage,
532 and contact tracing: An agent-based simulation study of COVID-19 for an urban region,” *Glob. Epidemiol.*,
533 vol. 2, no. 100036, Nov. 2020, doi: <https://doi.org/10.1016/j.gloepi.2020.100036>.
- 534 [8] “Evidence to recommendations for COVID-19 vaccines: Evidence framework,” *WHO*, Dec. 10, 2020.
535 Accessed: Jan. 25, 2020. [Online]. Available: [https://www.who.int/publications/i/item/WHO-2019-nCoV-](https://www.who.int/publications/i/item/WHO-2019-nCoV-SAGE-Framework-Evidence-2020-1)
536 [SAGE-Framework-Evidence-2020-1](https://www.who.int/publications/i/item/WHO-2019-nCoV-SAGE-Framework-Evidence-2020-1)
- 537 [9] “Framework for equitable allocation of COVID-19 vaccine.” The National Academy Press. Accessed: Jan. 25,
538 2021. [Online]. Available: <https://www.nap.edu/read/25917/chapter/1>
- 539 [10] K. Clements, J. Chancellor, N. Kristin, K. DeLong, and D. Thompson, “Cost-Effectiveness of a
540 Recommendation of Universal Mass Vaccination for Seasonal Influenza in the United States,” *Value Health*,
541 vol. 14, no. 6, pp. 800–811, Sep. 2011, doi: <https://doi.org/10.1016/j.jval.2011.03.005>.
- 542 [11] R. Patel, I. Longini, and E. Halloran, “Finding optimal vaccination strategies for pandemic influenza using
543 genetic algorithms,” *J. Theor. Biol.*, vol. 234, no. 2, pp. 201–212, May 2005, doi:
544 <https://doi.org/10.1016/j.jtbi.2004.11.032>.
- 545 [12] I. Longini and E. Halloran, “Strategy for Distribution of Influenza Vaccine to High-Risk Groups and
546 Children,” *Am. J. Epidemiol.*, vol. 161, no. 4, pp. 303–306, Feb. 2005, doi:
547 <https://doi.org/10.1093/aje/kwi053>.
- 548 [13] D. Knipl and G. Röst, “Modelling the strategies for age specific vaccination scheduling during influenza
549 pandemic outbreaks,” *Math Biosci Eng*, vol. 8, no. 11, pp. 123–139, Jan. 2011, doi: 10.3934/mbe.2011.8.123.
- 550 [14] G. Barmparis and G. Tsironis, “Estimating the infection horizon of COVID-19 in eight countries with a data-
551 driven approach,” *I35*, vol. 109842, May 2020, doi: 10.1016/j.[s.2020.109842.
- 552 [15] D. Candido, I. Claro, J. Jesus, W. Marciel de Souza, F. Moreira, and S. Dellicour, “Evolution and epidemic
553 spread of SARS-CoV-2 in Brazil,” *Science*, vol. 369, no. 6508, pp. 1255–1260, Sep. 2020, doi:
554 10.1126/science.abd2161.
- 555 [16] N. Chintalapudi, G. Battineni, and F. Amentaa, “COVID-19 virus outbreak forecasting of registered and
556 recovered cases after sixty day lockdown in Italy: A data driven model approach,” *J Microbiol Immunol*
557 *Infect*, vol. 53, no. 3, pp. 396–403, Jun. 2020, doi: 10.1016/j.jmii.2020.04.004.
- 558 [17] Y. Fang, Y. Nie, and M. Penny, “Transmission dynamics of the COVID-19 outbreak and effectiveness of
559 government interventions: A data-driven analysis,” *J Med Virol*, vol. 92, no. 6, pp. 645–659, doi:
560 10.1002/jmv.25750.
- 561 [18] S. Yang, P. Cao, P. Du, Z. Wu, Z. Zhang, and L. Yang, “Early estimation of the case fatality rate of COVID-
562 19 in mainland China: a data-driven analysis,” *Ann Transl Med*, vol. 8, no. 4, p. 128, Feb. 2020, doi:
563 10.21037/atm.2020.02.66.

- 564 [19] A. Aleta, D. Martin-Corral, A. Piontti, M. AJelli, M. Litvinova, and M. Chinazzi, “Modeling the impact of
565 social distancing, testing, contact tracing and household quarantine on second-wave scenarios of the COVID-
566 19 epidemic,” *Medrxiv*, May 2020, doi: <https://doi.org/10.1101/2020.05.06.20092841>.
- 567 [20] C. Hou, J. Chen, Y. Zhou, L. Hua, J. Yuan, and S. He, “The effectiveness of quarantine of Wuhan city against
568 the Corona Virus Disease 2019 (COVID-19): A well-mixed SEIR model analysis,” *J Med Virol*, vol. 92, no.
569 7, pp. 841–848, Jul. 2020, doi: <https://doi.org/10.1002/jmv.25827>.
- 570 [21] L. Peng, W. Yang, D. Zhang, C. Zhuge, and L. Hong, “Epidemic analysis of COVID-19 in China by
571 dynamical modeling,” *MedRxiv*, Feb. 2020, doi: <https://doi.org/10.1101/2020.02.16.20023465>.
- 572 [22] Z. Yang, Z. Zeng, K. Wang, S. Wong, W. Liang, and M. Zanin, “Modified SEIR and AI prediction of the
573 epidemics trend of COVID-19 in China under public health interventions,” *J Thorac Dis*, vol. 12, no. 3, pp.
574 165–174, Mar. 2020, doi: 10.21037/jtd.2020.02.64.
- 575 [23] Y. Zhang, B. Jiang, J. Yuan, and Y. Tao, “The impact of social distancing and epicenter lockdown on the
576 COVID-19 epidemic in mainland China: A data-driven SEIQR model study,” *MedRxiv*, Mar. 2020, doi:
577 <https://doi.org/10.1101/2020.03.04.20031187>.
- 578 [24] D. Chao, E. Halloran, V. Obenchain, and I. Longini, “FluTE, a publicly available stochastic influenza
579 epidemic simulation model,” *PLoS Comput Biol*, vol. 6, no. 1, p. e1000656, Jan. 2010, doi:
580 10.1371/journal.pcbi.1000656.
- 581 [25] H. Tatapudi and T. K. Das, “Impact of school reopening on pandemic spread: A case study using an agent-
582 based model for COVID-19,” *Infect. Dis. Model.*, vol. 6, pp. 839–847, 2021, doi: 10.1016/j.idm.2021.06.007.
- 583 [26] D. K. Chu *et al.*, “Physical distancing, face masks, and eye protection to prevent person-to-person
584 transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis,” *The Lancet*, vol. 395,
585 no. 10242, pp. 1973–1987, Jun. 2020, doi: 10.1016/S0140-6736(20)31142-9.
- 586 [27] C. Vazquez, “Coronavirus in Miami-Dade: Contact tracing failures and talk of how to spend federal money,”
587 *Local10*, Jul. 27, 2020. [https://www.local10.com/news/local/2020/07/27/coronavirus-in-miami-dade-contact-](https://www.local10.com/news/local/2020/07/27/coronavirus-in-miami-dade-contact-tracing-failures-and-talk-of-how-to-spend-federal-money/)
588 [tracing-failures-and-talk-of-how-to-spend-federal-money/](https://www.local10.com/news/local/2020/07/27/coronavirus-in-miami-dade-contact-tracing-failures-and-talk-of-how-to-spend-federal-money/) (accessed Jul. 30, 2021).
- 589 [28] “Contact Tracing Is Failing in Many States. Here’s Why,” *NY Times*, Jul. 31, 2020.
590 <https://www.nytimes.com/2020/07/31/health/covid-contact-tracing-tests.html> (accessed Jul. 30, 2021).
- 591 [29] Miami-Dade County Public Schools, “A guide to the reopening of Miami-Dade County public schools,”
592 *Reopen smart return safe*, Aug. 2020.
593 [http://pdfs.dadeschools.net/reopening/Reopen%20SMART%20Return%20SAFE%20-](http://pdfs.dadeschools.net/reopening/Reopen%20SMART%20Return%20SAFE%20-%20A%20Guide%20to%20the%20Reopening%20of%20Miami-Dade%20County%20Public%20Schools.pdf)
594 [%20A%20Guide%20to%20the%20Reopening%20of%20Miami-Dade%20County%20Public%20Schools.pdf](http://pdfs.dadeschools.net/reopening/Reopen%20SMART%20Return%20SAFE%20-%20A%20Guide%20to%20the%20Reopening%20of%20Miami-Dade%20County%20Public%20Schools.pdf)
595 (accessed Aug. 03, 2021).
- 596 [30] M. Beusokem, “Survey: COVID vaccine willingness waned since April,” *Center for Infectious Disease*
597 *Research and Policy*, Dec. 30, 2020. Accessed: Jan. 28, 2021. [Online]. Available:
598 <https://www.cidrap.umn.edu/news-perspective/2020/12/survey-covid-vaccine-willingness-waned-april>
- 599 [31] L. Saad, “U.S. Readiness to Get COVID-19 Vaccine Steadies at 65%,” *Gallup News*, Jan. 12, 2021. Accessed:
600 Jan. 28, 2021. [Online]. Available: [https://news.gallup.com/poll/328415/readiness-covid-vaccine-](https://news.gallup.com/poll/328415/readiness-covid-vaccine-steadies.aspx)
601 [steadies.aspx](https://news.gallup.com/poll/328415/readiness-covid-vaccine-steadies.aspx)
- 602 [32] CDC, “COVID-19 Pandemic Planning Scenarios,” *Centers for Disease Control and Prevention*.
603 [https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios-archive/planning-scenarios-2020-05-](https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios-archive/planning-scenarios-2020-05-20.pdf)
604 [20.pdf](https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios-archive/planning-scenarios-2020-05-20.pdf) (accessed May 05, 2021).
- 605 [33] N. M. Ferguson *et al.*, “Strategies for containing an emerging influenza pandemic in Southeast Asia,” *Nature*,
606 vol. 437, no. 7056, pp. 209–214, Sep. 2005, doi: 10.1038/nature04017.
- 607 [34] N. Ferguson, D. Cummings, C. Fraser, J. Cajka, P. Cooley, and D. Burke, “Estimating disease burden of a
608 potential A(H7N9) pandemic influenza outbreak in the United States,” *Nature*, vol. 442, no. 7101, pp. 448–
609 452, Apr. 2006, doi: <https://doi.org/10.1038/nature04795>.
- 610 [35] “Florida’s COVID-19 Data and Surveillance Dashboard,” *Florida Department of Health, Division of Disease*
611 *Control and Health Protection*.
- 612 [36] “Evidence summary for COVID-19 viral load over course of infection,” *Health Information and Quality*
613 *Authority*, 2020. [https://www.hiqa.ie/sites/default/files/2020-04/Evidence-Summary_COVID-19_duration-of-](https://www.hiqa.ie/sites/default/files/2020-04/Evidence-Summary_COVID-19_duration-of-infectivity-viral-load_0.pdf)
614 [infectivity-viral-load_0.pdf](https://www.hiqa.ie/sites/default/files/2020-04/Evidence-Summary_COVID-19_duration-of-infectivity-viral-load_0.pdf) (accessed Jul. 30, 2021).
- 615